Northleaf Venture Catalyst Fund (NVCF), a joint initiative between major Canadian institutional investors and the Governments of Canada and Ontario, has made a $15m lead commitment to Lumira Capital IV.
Lumira Capital IV a late-stage venture capital fund investing in high-potential biopharmaceutical and medical device companies
The commitment to Lumira extends a partnership that began in 2012, when the Northleaf-managed Ontario Venture Capital Fund (OVCF) made an investment in Lumira’s prior fund.
The partnership was further strengthened through NVCF’s direct co-investment in 2015 alongside Lumira in Vancouver-based Zymeworks Inc., a biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
In May 2017, Zymeworks closed its initial public offering (IPO).
Led by Ian Carew, Director, Northleaf Capital Partners invests primarily in Canada-based venture capital and growth equity funds and direct co-investments that support innovative, high growth companies. Following the investment in Lumia, it has now completed the NVCF investment program, with a total of $300m committed to a diversified portfolio of 13 fund investments and 11 direct investments.